Kai Chu

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Yanjun Zhang, Gang Zeng, Hongxing Pan et al. · The Lancet Infectious Diseases · 2020 · 1.5K citations · Full text

Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Fengcai Zhu, Fanyue Meng, Jingxin Li et al. · The Lancet · 2013 · 382 citations

Vaccination, Vaccine Safety, Vaccine Development +5

Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials

Gang Zeng, Qianhui Wu, Hongxing Pan et al. · The Lancet Infectious Diseases · 2021 · 284 citations · Full text

Vaccination, Vaccine Safety, Coronary Unit +8

Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial

Fengcai Zhu, Lihua Hou, Jingxin Li et al. · The Lancet · 2015 · 187 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +7

Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial

You‐Lin Qiao, Ting Wu, Rongcheng Li et al. · JNCI Journal of the National Cancer Institute · 2019 · 172 citations · Full text